

# MANAGEMENT SYSTEM CERTIFICATE

Certificate no.:  
258756-2018-AQ-POL-RvA

Initial certification date:  
06 April 2012

Valid:  
06 April 2021 – 05 April 2024

## Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – Państwowy Instytut Badawczy

ul. W.K. Roentgena 5, 02-781 Warszawa, Poland

and the sites as mentioned in the appendix accompanying this certificate

has been found to conform to the Quality Management System standard:  
**ISO 9001:2015**

This certificate is valid for the following scope:

### I. Provision of medical services in the scope of:

1. Hospital treatment - services in wards.
2. Hospital treatment - radiotherapy, brachytherapy, isotopic therapy.
3. Hospital treatment - chemotherapy.
4. Hospital treatment - drug program.
5. Ambulatory specialist care - services in outpatient clinics.
6. Outpatient specialist care - cost-intensive diagnostics.
7. Services contractually.
8. Therapeutic rehabilitation.
9. Psychiatric care and treatment of addictions.
10. Preventive health programs.
11. Implementation of the National Program for Combating Cancer.
12. Palliative and hospice care.
13. Comprehensive oncological care for the recipient with breast cancer (KON-PIERŚ)
14. Comprehensive oncology care for the colorectal cancer patient (KON-JELITO)

### II. Conducting scientific and research work.

Place and date:  
Gdynia, 27 April 2023

For the issuing office:  
DNV - Business Assurance  
ul. Łużycka 6e, 81-537 Gdynia, Poland



Tomasz Słupek  
Management Representative

## Appendix to Certificate

### Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – Państwowy Instytut Badawczy

Locations included in the certification are as follows:

Site Name	Site Address	Site Scope
Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – Państwowy Instytut Badawczy	ul. W.K. Roentgena 5, 02-781 Warszawa, Poland	<p>Contracts with the National Health Fund</p> <p>Scope of certification:</p> <ol style="list-style-type: none"> <li>Hospital treatment - services in the fields of: anaesthesiology and intensive therapy, anaesthesiology, thoracic surgery, general surgery, oncological surgery, maxillo-facial surgery, endocrinology gastroenterology, oncological gynaecology, haematology, neurosurgery, clinical oncology, otorhinolaryngology, urology, cardiology,</li> <li>Hospital treatment - radiotherapy, brachytherapy, isotope therapy in the fields of: teleradiotherapy, brachytherapy, isotope therapy.</li> <li>Hospital treatment - chemotherapy in the following ranges: outpatient treatment, one-day treatment, hospital treatment.</li> <li>Hospital treatment - drug programmes in the scope of: treatment programmes: breast cancer, kidney cancer, malignant lymphomas, hepatocellular carcinoma, colorectal cancer, stroma of the gastrointestinal tract, Leśniewski - Crohn's disease, soft tissue sarcomas, lung cancer and mesothelioma, ovarian cancer or peritoneal cancer, ovarian cancer, highly differentiated neuroendocrine tumour of the pancreas, squamous cell carcinoma of the head and neck organs, patients with plasmocytic myeloma, ulcerative colitis UC, castration-resistant prostate cancer, oesophageal and gastric cancer, melanoma of the skin or mucous membranes, acute leukaemia chronic lymphocytic leukaemia, patients with pancreatic adenocarcinoma, patients with advanced basal cell carcinoma of the skin, patients suffering from classic form of Hodgkin's disease, aggressive inoperable thyroid medullary carcinoma, patients suffering from B-cell lymphomas, patients suffering from T-cell lymphoma, patients suffering from advanced squamous cell carcinoma with cemiplimab, patients suffering from progressing, locally advanced or metastatic, diversified (papillary/follicular/oxyphilic – Hurthle cell) thyroid cancer, resistant to therapy with radioactive iodine, Merkel cell carcinoma with awelumab, patients with Cushing's disease, patients with idiopathic multicentric Castleman disease, patients with advanced cancer encompassing bones with the use of denosumab, patients with neuroendocrine tumours of gastrointestinal system with the use of radiopharmaceuticals, patients with urothelial carcinoma, patients with solid tumours with gene fusion of neurotrophic tyrosine kinase (NTRK).</li> <li>Outpatient specialist care - services in outpatient clinics within the following areas: thoracic surgery, general surgery, oncological surgery, maxillo-facial surgery, gastroenterology, gynaecology and obstetrics, neurosurgery, clinical oncology, urology, pain treatment, genetics, endocrinology, cardiology and neurology, metabolic diseases.</li> <li>Outpatient specialist care - cost-intensive diagnostics in the following areas: nuclear medicine examinations, gastroscopy, colonoscopy, computed tomography, magnetic resonance imaging.</li> <li>Separately contracted services in the following areas: isotope testing, isotope therapy, genetic testing, genetic testing for persons under 18</li> </ol>

Site Name	Site Address	Site Scope
		<p>years of age, Positron Emission Tomography, care over families with high genetic risk of colon cancer or endometrial cancer.</p> <p>8. Rehabilitation treatment in the following areas: medical outpatient rehabilitation care, outpatient physiotherapy, systemic rehabilitation in a day centre.</p> <p>9. Psychiatric care and treatment of addiction in the field of: outpatient psychiatric services for adults.</p> <p>10. Preventive health programmes in the areas of prevention of: breast cancer at primary and extended stages, cervical cancer at primary, diagnostic and extended stages, tobacco-related diseases.</p> <p>11. Palliative and hospice care.</p> <p>12. Comprehensive oncological care for the recipient with breast cancer (KON-PIERŚ).</p> <p>13. Comprehensive oncology care for the colorectal cancer patient (KON-JELITO)</p> <p>Contracts with the Ministry of Health.</p> <p>Implementation of the National Cancer Control Programme in the following fields:</p> <ol style="list-style-type: none"> <li>1. Primary prevention of cancer.</li> <li>2. Population-based Breast Cancer Prevention and Early Detection Programme.</li> <li>3. Population-based Cervical Cancer Prevention and Early Detection Programme.</li> </ol>
<p>Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – Państwowy Instytut Badawczy</p>	<p>ul. Wawelska 15, 02-034 Warszawa, Poland</p>	<p>Contracts with the National Health Fund.</p> <p>Scope of certification:</p> <ol style="list-style-type: none"> <li>1. Hospital treatment - services in wards in the following areas: anaesthesiology and intensive care, general surgery, oncological surgery.</li> <li>2. Ambulatory Specialised Care - services in outpatient clinics in the following areas: general surgery, oncological surgery, clinical oncology.</li> <li>3. Outpatient specialised care - cost-intensive diagnostics in: computed tomography.</li> <li>4. Hospital treatment - radiotherapy in scope: teleradiotherapy.</li> <li>5. Hospital treatment - drug programmes in treatment areas: <ol style="list-style-type: none"> <li>1) Breast cancer,</li> <li>2) Rectal cancer,</li> <li>3) Lung cancer and mesothelioma,</li> <li>4) Highly differentiated neuroendocrine tumour of the pancreas,</li> <li>5) Castration-resistant prostate cancer,</li> <li>6) Hepatocellular carcinoma,</li> <li>7) Renal cell carcinoma,</li> <li>8) oesophageal and cancer.</li> <li>9) of adenocarcinoma of the pancreas</li> <li>10) of cancer encompassing bones with denosumab.</li> </ol> </li> <li>6. Hospital treatment - chemotherapy in the following ranges: outpatient treatment, one-day treatment, hospital treatment.</li> </ol>